MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma

Cancer Epidemiology

Volumn 38, Issue 4, 2014, Pages 408-413

  Yu, Lingxiang ^a   Zhang, Jiabin ^a   Guo, Xiaodong ^a   Li, Zhiwei ^a   Zhang, Peirui ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

AKT; Hepatocellular carcinoma; Microrna 224; Prognosis; Tumor progression

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA; MICRORNA 224; PROTEIN KINASE B; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN224 MICRORNA, HUMAN;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR DIAGNOSIS; UPREGULATION; AGED; BIOSYNTHESIS; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84904563942     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.05.001     Document Type: Article

References (43)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Dhir M., Lyden E.R., Smith L.M., Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford) 2012, 14:635-645.
3. Zhu A.X. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol 2012, 39:493-502.
4. Tanaka S., Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 2012, 39:486-492.
5. Witjes C.D., van Aalten S.M., Steyerberg E.W., Borsboom G.J., de Man R.A., Verhoef C., et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2013, 7:59-64.
6. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006, 11:441-450.
7. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
8. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
9. Huang S., He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011, 104:235-240.
10. Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012, 4:143-159.
11. Lin L., Lin Y., Jin Y., Zheng C. Microarray analysis of microRNA expression in liver cancer tissues and normal control. Gene 2013, 523:158-160.
12. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006, 99:671-678.
13. Elhefnawi M., Soliman B., Abu-Shahba N., Amer M. An integrative meta-analysis of microRNAs in hepatocellular carcinoma. Genomics Proteomics Bioinformatics 2013, 11:354-367.
14. Li J., Shi W., Gao Y., Yang B., Jing X., Shan S., et al. Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. Clin Lab 2013, 59:1009-1015.
15. Zhang Y., Guo X., Xiong L., Kong X., Xu Y., Liu C., et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett 2012, 586:4362-4370.
16. Lan S.H., Wu S.Y., Zuchini R., Lin X.Z., Su I.J., Tsai T.F., et al. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of miR-224. Hepatology 2014, 59:505-517.
17. Mees S.T., Mardin W.A., Sielker S., Willscher E., Senninger N., Schleicher C., et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009, 16:2339-2350.
18. Li Q., Ding C., Chen C., Zhang Z., Xiao H., Xie F., et al. miR-224 promotes cell migration and invasion by modulating p-PAK4 and MMP-9 via targeting HOXD10 in human hepatocellular carcinoma. J Gastroenterol Hepatol 2013, (in press).
19. Li H., Li Y., Liu D., Sun H., Liu J. miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. Cell Physiol Biochem 2013, 32:448-458.
20. Ma D., Tao X., Gao F., Fan C., Wu D. miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 2012, 4:483-488.
21. Zhang Y., Guo X., Yang M., Yu L., Li Z., Lin N. Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interaction network analysis and clinical validation. Mol Biosyst 2014, 10:215-222.
22. Kandel E.S., Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999, 253:210-229.
23. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905-2927.
24. Aoki M., Batista O., Bellacosa A., Tsichlis P., Vogt P.K. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA 1998, 95:14950-14955.
25. Yip P.Y., Cooper W.A., Kohonen-Corish M.R., Lin B.P., McCaughan B.C., Boyer M.J., et al. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. J Clin Pathol 2014, 67:333-340.
26. Broek R.V., Mohan S., Eytan D.F., Chen Z., Van Waes C., The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, crosstalk, and therapies. Oral Dis 2013, (in press).
27. Sun X.P., Dong X., Lin L., Jiang X., Wei Z., Zhai B., et al. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. FEBS J 2014, 281:115-128.
28. Sasaki T., Kuniyasu H., Luo Y., Kitayoshi M., Tanabe E., Kato D., et al. AKT activation and telomerase reverse transcriptase expression are concurrently associated with prognosis of gastric cancer. Pathobiology 2014, 81:36-41.
29. Nijkamp M.M., Span P.N., Stegeman H., Grénman R., Kaanders J.H., Bussink J. Low phosphorylated AKT expression in laryngeal cancer: indications for a higher metastatic risk. Int J Radiat Oncol Biol Phys 2013, 87:349-355.
30. Agarwal E., Brattain M.G., Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 2013, 25:1711-1719.
31. Guo X., Xiong L., Zou L., Zhao J. Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res 2012, 18:635-640.
32. Guo X., Xiong L., Sun T., Peng R., Zou L., Zhu H., et al. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn Pathol 2012, 7:44.
33. Guo X., Xiong L., Zou L., Sun T., Zhang J., Li H., et al. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival. Diagn Pathol 2012, 7:96.
34. Zhang G.J., Zhou H., Xiao H.X., Li Y., Zhou T. Up-regulation of miR-224 promotes cancer cell proliferation and invasion and predicts relapse of colorectal cancer. Cancer Cell Int 2013, 13:104.
35. Shen S.N., Wang L.F., Jia Y.F., Hao Y.Q., Zhang L., Wang H. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn Pathol 2013, 8:69.
36. Boguslawska J., Wojcicka A., Piekielko-Witkowska A., Master A., Nauman A. MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS ONE 2011, 6:e24541.
37. Zhou F., Li S., Meng H.M., Qi L.Q., Gu L. MicroRNA and histopathological characterization of pure mucinous breast carcinoma. Cancer Biol Med 2013, 10:22-27.
38. Scapoli L., Palmieri A., Lo Muzio L., Pezzetti F., Rubini C., Girardi A., et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010, 23:1229-1234.
39. Wu H., Haag D., Muley T., Warth A., Zapatka M., Toedt G., et al. Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. Genes Chromosomes Cancer 2013, 52:250-264.
40. Mavridis K., Stravodimos K., Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 2013, 59:261-269.
41. Zhang Y., Takahashi S., Tasaka A., Yoshima T., Ochi H., Chayama K. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol 2013, 28:565-575.
42. Wang Y., Lee A.T., Ma J.Z., Wang J., Ren J., Yang Y., et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008, 283:13205-13215.
43. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103:307-312.